3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Leukemia, Myeloid, Acute
104
Multiple Myeloma
66
Lymphoma
60
Precursor Cell Lymphoblastic Leukemia-Lymphoma
57
Myelodysplastic Syndromes
51
Lymphoma, Non-Hodgkin
51
Leukemia
50
Hodgkin Disease
42
Lymphoma, Mantle-Cell
29
Lymphoma, Large B-Cell, Diffuse
29
Leukemia, Lymphocytic, Chronic, B-Cell
26
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
23
Lymphoma, Follicular
22
Burkitt Lymphoma
22
Breast Neoplasms
22
Recurrence
20
Neoplasms, Plasma Cell
18
Neuroblastoma
17
Hematologic Neoplasms
17
Lymphoma, B-Cell, Marginal Zone
15
Myeloproliferative Disorders
14
Lymphoma, Large-Cell, Immunoblastic
14
Leukemia, Myelomonocytic, Chronic
12
Leukemia, Biphenotypic, Acute
12
Congenital Abnormalities
12
Blast Crisis
10
Anemia, Refractory, with Excess of Blasts
10
Retinoblastoma
9
Central Nervous System Neoplasms
9
Sarcoma
8
Interventions
Specimen Handling
1
Granulocyte Colony-Stimulating Factor
1
Genetic Counseling
1
Filgrastim
1
Decitabine
1
Clinical Trials, Phase I as Topic
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Congenital Bone Marrow Failure Syndromes
×
Granulocyte Colony-Stimulating Factor
×
Clear all
NCT05796570
2026-03-19
MORE
Dana-Farber Cancer Institute
Phase 2
Recruiting
37 enrolled